Risks and benefits from CDK inhibitors for advanced HR1 Her 22 breast cancer

C. Messina, M. Messina, E. Zanardi

Research output: Contribution to journalLetter

Original languageEnglish
Pages (from-to)3099-3100
Number of pages2
JournalAnnals of Oncology
Volume28
Issue number12
DOIs
Publication statusPublished - Dec 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Risks and benefits from CDK inhibitors for advanced HR1 Her 22 breast cancer. / Messina, C.; Messina, M.; Zanardi, E.

In: Annals of Oncology, Vol. 28, No. 12, 01.12.2017, p. 3099-3100.

Research output: Contribution to journalLetter

Messina, C. ; Messina, M. ; Zanardi, E. / Risks and benefits from CDK inhibitors for advanced HR1 Her 22 breast cancer. In: Annals of Oncology. 2017 ; Vol. 28, No. 12. pp. 3099-3100.
@article{58984aa649c542f286e4ad234fb5b1a4,
title = "Risks and benefits from CDK inhibitors for advanced HR1 Her 22 breast cancer",
author = "C. Messina and M. Messina and E. Zanardi",
year = "2017",
month = "12",
day = "1",
doi = "10.1093/annonc/mdx530",
language = "English",
volume = "28",
pages = "3099--3100",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - Risks and benefits from CDK inhibitors for advanced HR1 Her 22 breast cancer

AU - Messina, C.

AU - Messina, M.

AU - Zanardi, E.

PY - 2017/12/1

Y1 - 2017/12/1

UR - http://www.scopus.com/inward/record.url?scp=85042164877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042164877&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx530

DO - 10.1093/annonc/mdx530

M3 - Letter

VL - 28

SP - 3099

EP - 3100

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -